{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
lasmiditan
to a specific field?
There is one exact (name or code) match for lasmiditan
Status:
US Approved Rx
(2019)
Source:
NDA211280
(2019)
Source URL:
First approved in 2019
Source:
NDA211280
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
LASMIDITAN is a serotonin (5-HT) receptor agonist without vasoconstrictor activity, which selectively binds to the 5-HT(1F) receptor subtype. It is under development for the treatment of migraine.
Showing 1 - 6 of 6 results
Status:
US Approved Rx
(2019)
Source:
NDA211280
(2019)
Source URL:
First approved in 2019
Source:
NDA211280
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
LASMIDITAN is a serotonin (5-HT) receptor agonist without vasoconstrictor activity, which selectively binds to the 5-HT(1F) receptor subtype. It is under development for the treatment of migraine.
Status:
US Approved Rx
(2013)
First approved in 1958
Class:
MIXTURE
Status:
US Approved Rx
(2019)
Source:
NDA211280
(2019)
Source URL:
First approved in 2019
Source:
NDA211280
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
LASMIDITAN is a serotonin (5-HT) receptor agonist without vasoconstrictor activity, which selectively binds to the 5-HT(1F) receptor subtype. It is under development for the treatment of migraine.
Status:
US Approved Rx
(2019)
Source:
NDA211280
(2019)
Source URL:
First approved in 2019
Source:
NDA211280
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
LASMIDITAN is a serotonin (5-HT) receptor agonist without vasoconstrictor activity, which selectively binds to the 5-HT(1F) receptor subtype. It is under development for the treatment of migraine.
